AUS
NZ
UK
CA
USA
IND
Highlights
- Asset Management One Co. Ltd. reduces its holdings in Henry Schein by 6.6% in the fourth quarter.
- Henry Schein receives mixed ratings from analysts, with an overall "Moderate Buy" consensus.
- The company invests in healthcare distribution and tech services, exhibiting stable financial performance.
Henry Schein, Inc. (NASDAQ:HSIC) recently experienced shifts in its institutional holdings. Asset Management One Co. Ltd. reduced its stake by 6.6% during the fourth quarter, owning 51,498 shares valued at $3,626,000. This decision aligns with the actions of other hedge funds and institutions, which have been buying and selling shares of HSIC to balance their portfolios.
Investors such as Cromwell Holdings LLC and Versant Capital Management Inc. have significantly increased their positions, showcasing diverse investment strategies. Cromwell Holdings LLC almost doubled its stake, while Versant Capital Management Inc. increased its holdings by 274.6%. These movements depict the dynamic nature of institutional investments in Henry Schein's stock.
Analyst Ratings and Market Performance
Analysts have presented various perspectives on Henry Schein's stock. Bank of America upgraded the company from "underperform" to "buy," raising the price objective from $69.00 to $84.00. In contrast, Jefferies Financial Group maintains a "hold" rating, reflecting a more cautious outlook.
The analyst consensus leans toward a "Moderate Buy," with a consensus price target of $80.09. With investment strategies differing among analysts, the company's market trajectory is a subject of intrigue within the investment community.
Company Overview
Henry Schein operates in the healthcare domain, providing products and services to dental practitioners, laboratories, physician practices, and more. The company's focus spans two segments: Health Care Distribution and Technology and Value-Added Services. This diversified approach supports its resilience and market presence.
Trading at $77.83, Henry Schein's market capitalization stands at $9.70 billion. It demonstrates a steady price-to-earnings ratio and strategic financial metrics, such as a beta of 0.91, which reflects its market stability compared to broader indices.
Henry Schein continues to be a focal point for institutional investors and analysts alike. Its strategic realignments in holdings and diversified operational focus contribute to its position in the healthcare sector. While analysts differ in their opinions on the stock's potential, Henry Schein remains a prominent entity with a broad scope of influence in its field.
